Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer: Survival analysis of the phase II randomized DEEPER trial by JACCRO.
Authors
Yu Sunakawa
Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan;
Yu Sunakawa , Manabu Shiozawa , Takanori Watanabe , Hirofumi Ota , Hisateru Yasui , Taichi Yabuno , Mitsuyoshi Tei , Mitsugu Kochi , Dai Manaka , Hisatsugu Ohori , Tatsuro Yamaguchi , Tamotsu Sagawa , Masahito Kotaka , Yutaro Kubota , Takashi Sekikawa , Masato Nakamura , Masahiro Takeuchi , Wataru Ichikawa , Masashi Fujii , Akihito Tsuji
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02515734
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 120)
DOI
10.1200/JCO.2023.41.4_suppl.120
Abstract #
120
Poster Bd #
F17
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO.
First Author: Veronica Conca
Poster
2021 Gastrointestinal Cancers Symposium
Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).
First Author: Takanori Watanabe
Poster
2017 Gastrointestinal Cancers Symposium
A randomized phase II study to investigate the deepness of response (DpR) of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer (mCRC) patients with RAS wild-type tumors: DEEPER.
First Author: Akihito Tsuji
Poster
2014 ASCO Annual Meeting
Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.
First Author: Chiara Cremolini